ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2060 entries already.
Takeda, Boehringer Ingelheim and Novartis do it repeatedly. Global players make major investments in their Austrian facilities. Not only multinationals but start-ups and scale-ups such as Apeiron Biologics and ViraTherapeutics benefit from a comprehensive ecosystem – from basic research to production and distribution. The business location agency ABA is the first point of contact for setting up operations in Austria.
Eppendorf Tubes® BioBased reduce the product-specific carbon footprint and support environmental friendly lab workflow.
Antibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.
Keeping biologicals at low temperatures is an established and effective way of maintaining their potency. This is critical for many types of medicines, vaccines, reagents, and biological samples, which is the reason why laboratories, hospitals, clinics, pharmacies, and more employ medical-grade refrigerators to protect their samples from ambient conditions.
Catalonia’s healthcare start-ups raised €238m in 2021, a new record and 4% up from 2020. Four fifth (83%) of VC came from international investors.
The European Council has adopted three regulations aimed at improving pandemic preparedness, which together with two other pillars complete the EU Health Union.
Automotive company Audi AG and gas fermentation specialist Krajete GmbH are building a highly effective industrial-scale CO2 Direct Air Capturing plant in Linz.
With its strategic location on the Martinsried campus, the IZB offers an outstanding opportunity to found a company in the vicinity of science and industry.
Therapies for autoreactive immune disorders have greatly advanced in the past decades but often have significant side effects. Marinomed Biotech AG strives to improve therapies by increasing the solubility and bioavailability of existing drugs. A proprietary pipeline and Solv4U, a B2B offering for API solubilization, enable the development of clinically meaningful new or improved therapies.
Finnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.